Why AstraZeneca Stock Was a Winner Today
Good news from the laboratory put some zip into (NASDAQ: AZN) shares on Monday. The veteran pharmaceutical company's shares enjoyed a nearly 3% lift across the trading session as a consequence, a rate that convincingly outpaced the S 500 index's 1.5% growth.
Early this morning, AstraZeneca shared the results of a phase 3 clinical trial of baxdrostat, its investigational drug for treatment-resistant hypertension (i.e., high blood pressure).
Image source: Getty Images.
Source Fool.com
Astrazeneca ADR Stock
€78.50
0.650%
The community is currently still undecided about Astrazeneca ADR with 1 Buy predictions and 0 Sell predictions.
As a result the target price of 80 € shows a slightly positive potential of 1.91% compared to the current price of 78.5 € for Astrazeneca ADR.
